Recruiting studies: Stage Ii Colon Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924 Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07448142 Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cance
Phase 3 · 1 location(s) · Fudan University · NCT05954078 Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treat
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07047560 Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT04221893 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT06887218 MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
NA · 1 location(s) · Sun Yat-sen University · NCT06204484 Family Communications After Genetic Testing
NA · 276 location(s) · Alliance for Clinical Trials in Oncology · NCT07143487 Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Phase 2/Phase 3 · 16 location(s) · Centre Hospitalier Universitaire de Besancon · NCT05462613 SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06850103 GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06558773 XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302 Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Phase 2 · 1 location(s) · National Cancer Centre, Singapore · NCT04912765 OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Phase 2 · 2 location(s) · Karen-Lise Garm Spindler · NCT04680260 The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
Phase N/A · 1 location(s) · Case Comprehensive Cancer Center · NCT04624555 Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Phase 1/Phase 2 · 87 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT04930432 Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Meta
Phase 2 · 1 location(s) · Dominik Paul Modest · NCT05007132 Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cance
NA · 13 location(s) · City of Hope Medical Center · NCT07125729 CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000 Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
Phase 2 · 1 location(s) · Shanghai Pudong Hospital · NCT07106034 FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis
Phase 2 · 1 location(s) · Hua Jiang · NCT06801665 Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS
Phase 2 · 1 location(s) · Fudan University · NCT06218810 A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07071714 Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Phase 3 · 3 location(s) · Seoul National University Hospital · NCT05534087 A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816 Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05194878 Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Phase 2/Phase 3 · 1 location(s) · Chungnam National University Hospital · NCT05179889 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Muta
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03190941 Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · NCT06819215 RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based
NA · 9 location(s) · University of Aarhus · NCT06614647

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.